@AllbridgeCap

Backing ambition.

 Australia
Joined November 2016
  • Tweets4K
  • Following774
  • Followers358
1.6KMedia
“This allows for a potentially broader efficacy and reduces the likelihood for the development of viral drug resistance.”
1
From updated preprint co-authored by @US_FDA scientists, re: @MolecularPrtnrs @Novartis DARPin antiviral ensovibep "retain inhibitory potency against all frequent SARS-CoV-2 variants, including Omicron BA.1 and BA.2, as of February 2022." biorxiv.org/content/10.1101/…
Shai Biran@ShaiBiran28 Feb 2022
For those following our #covid19 program, we have recently updated ourbioRxiv with data showing ensovibep remains fully active against Omicron BA.2 too - biorxiv.org/content/10.1101/…

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants

SARS-CoV-2 has infected millions of people globally and continues to undergo evolution. Emerging variants can be partially resistant to vaccine induced immunity and therapeutic antibodies, emphasiz...

biorxiv.org
1
1
2
Excellent speech by the President of Ukraine to the people of Russia. One for the history books.

President Zelenskyy's speech to the Russian people

Ukrainian President Volodymyr Zelenskyy's plea to the Russian people in video remarks posted early on Feb. 24 local time with English subtitles.

117
2,441
262
7,962
1
Why Ensovibep should be a highly effective anti-viral against all variants of COVID
1
This is not good news #covid19 #sotrovimab #OmicronVariant
This Post is from a suspended account. Learn more
15
23
4
78
Ensovibep is designed to simultaneously bind the #COVID19 virus in 3 places. We recently shared positive results from our global study of ensovibep in patients demonstrating 78% reduction of the risk of hospitalization, emergency room visits, or death: bit.ly/3tfS6b3
3
6
If Pfizer hits the $22B in paxlovid number this year, it will likely make it (no surprise) the largest selling drug in the world. Humira did $20.7B in 2021.
7
15
3
71
”This indicates that epithelial cell intrinsic antiviral responses are insufficient for the clearance of SARS-CoV-2, implying an essential role for tissue-resident and infiltrating immune cells for eventual viral clearance from infected airway tissue” journals.asm.org/doi/10.1128…
3
4
Likely to see a repeat of Paxlovid rush to order where US placed $20bn order with Pfizer. Game over for @healthgovau order for a while. forbes.com/sites/zacharysmit…
1
Novartis and @MolecularPrtnrs admitted vaccinated and unvaccinated patients into their #COVID19 trial if a RAT was positive. Makes sense. Powerful anti-viral, 🙏 @tburton
Recent update from Novartis: in discussions with US gov and other governments (as well as FDA re EUA re sub-cue jab). Hope @healthgovau is in the queue this time. Ensovibep could be a highly scaleable GP-based rapid treatment. @ProfPCDoherty
COVID-19 can cause lasting damage to the cardiovascular system, even in “mild” cases that didn’t require hospitalisation during the acute phase of infection. A new study shows we’re going to see more heart disease, strokes, blood clots & other problems.🧵 nature.com/articles/s41591-0…
129
1,763
404
3,322
FY22 guidance exclusing any revenue from pot. APAs for $MOLN ensovibep, $NVS CEO confirming discussions with governments and "interested parties" though, probably more info later in Q1 or Q2
1
1
allbridge retweeted
UZH Alumni@uzhalumni4 Feb 2022
💡Public lecture: Ensovibep – a journey from basic research to the development of a promising Covid-19 drug 📅 8.2.2022, 12 p.m., on Zoom 👨‍🔬 Andreas Plückthun, Professor for Biochemistry at @UZH_ch & Michael Tobias Stumpp, co-founder of @MolecularPrtnrs uzhalumni.ch/events/78415
3
8
Interesting background re Pfizer anti-viral @ProfPCDoherty
Michael Lin, MD PhD 🧬@michaelzlin3 Feb 2022
Thank you @LauermanJohn for revealing the untold origin story for Pfizer's Paxlovid COVID-19 pill. The interesting part: Merck's drug boceprevir provided an essential backbone structure for Paxlovid, and boceprevir is still under patent. bloomberg.com/news/articles/…
1
allbridge retweeted
Eric Topol
@EricTopol3 Feb 2022
The countries that will not reach 70% 2-shot vaccinated by mid-2022. One is the 3rd largest in population and among the richest in the world
Edouard Mathieu@redouad3 Feb 2022
Update: We now project that 122 countries – including Bangladesh, Egypt, Ethiopia, Nigeria, Pakistan, Russia, and the United States – are not on track for the WHO's target of 70% of the population fully vaccinated by mid-2022. Read more: ourworldindata.org/covid-vac…
80
634
94
1,379
Load more